Benchmark Maintains Buy on Biofrontera, Lowers Price Target to $2.75
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $7 to $2.75.
Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $7 to $2.75.